ProBiotix Health, a UK-based life sciences company specialising in probiotic solutions for cardiometabolic health, has signed an exclusive supply agreement with Kemin China Technology Co Ltd (KCG). The deal grants KCG the rights to sell ProBiotix’s proprietary probiotic strain, LPLDL®, as a cardiometabolic health supplement ingredient in China, Hong Kong, and Macau, with potential expansion into other regions.
Under the agreement, ProBiotix will supply LPLDL® in bulk, and KCG will market it under a co-branding arrangement. China’s cardiovascular disease burden affects over 330 million people, and the country’s probiotic supplement market, valued at $2.3 billion in 2024, is projected to reach $3.6 billion by 2028.
KCG is a subsidiary of Kemin Industries, a U.S.-based global ingredient supplier with more than $1 billion in revenue and over 500 patents. The partnership is expected to create a long-term revenue stream for both companies and expand ProBiotix’s presence in the Chinese market.
